AMG National Trust Bank lifted its holdings in Humana Inc. (NYSE:HUM - Free Report) by 105.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 12,182 shares of the insurance provider's stock after buying an additional 6,243 shares during the quarter. AMG National Trust Bank's holdings in Humana were worth $3,223,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Vanguard Group Inc. increased its holdings in shares of Humana by 15.8% in the 4th quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider's stock valued at $3,254,899,000 after acquiring an additional 1,751,857 shares during the period. Dodge & Cox increased its holdings in shares of Humana by 106.7% in the 4th quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider's stock valued at $2,587,345,000 after acquiring an additional 5,264,045 shares during the period. Pzena Investment Management LLC increased its holdings in shares of Humana by 6.1% in the 1st quarter. Pzena Investment Management LLC now owns 3,828,923 shares of the insurance provider's stock valued at $1,013,133,000 after acquiring an additional 219,541 shares during the period. Geode Capital Management LLC increased its holdings in shares of Humana by 2.3% in the 4th quarter. Geode Capital Management LLC now owns 2,883,614 shares of the insurance provider's stock valued at $729,658,000 after acquiring an additional 63,562 shares during the period. Finally, Invesco Ltd. increased its holdings in shares of Humana by 29.8% in the 4th quarter. Invesco Ltd. now owns 2,397,808 shares of the insurance provider's stock valued at $608,348,000 after acquiring an additional 550,692 shares during the period. 92.38% of the stock is currently owned by hedge funds and other institutional investors.
Humana Price Performance
NYSE:HUM traded up $0.49 during trading hours on Wednesday, hitting $231.61. 747,677 shares of the stock were exchanged, compared to its average volume of 1,700,764. Humana Inc. has a 52-week low of $206.87 and a 52-week high of $406.09. The firm's fifty day moving average price is $234.87 and its 200 day moving average price is $257.29. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.71. The company has a market cap of $27.95 billion, a P/E ratio of 16.38, a P/E/G ratio of 1.53 and a beta of 0.44.
Humana (NYSE:HUM - Get Free Report) last issued its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, topping the consensus estimate of $10.07 by $1.51. The business had revenue of $32.11 billion for the quarter, compared to analysts' expectations of $32 billion. Humana had a return on equity of 14.47% and a net margin of 1.42%. The business's revenue for the quarter was up 8.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $7.23 EPS. As a group, equities research analysts anticipate that Humana Inc. will post 16.47 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of research firms have recently weighed in on HUM. Mizuho raised their price objective on Humana from $305.00 to $316.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 9th. Bank of America lowered their price objective on Humana from $320.00 to $260.00 and set a "neutral" rating for the company in a research report on Tuesday, June 17th. Barclays set a $268.00 price objective on Humana and gave the stock an "equal weight" rating in a research report on Thursday, June 12th. Oppenheimer lifted their price target on Humana from $300.00 to $310.00 and gave the stock an "outperform" rating in a research report on Thursday, May 1st. Finally, Truist Financial lowered their price target on Humana from $280.00 to $260.00 and set a "hold" rating for the company in a research report on Wednesday, July 16th. Sixteen equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $282.57.
View Our Latest Analysis on Humana
Humana Company Profile
(
Free Report)
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Stories
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
